Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. (Q38989597)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

based on heuristic

inferred from title

Morten F Gjerstorff

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Henrik J. Ditzel

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

D Elias

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

H Vever

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A-V Lænkholm

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

C W Yde

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

A E Lykkesfeldt

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

language of work or name

0 references

publication date

2 June 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

34

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1919-1927

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

https://scigraph.springernature.com/pub.10.1038/onc.2014.138

0 references

Tamoxifen in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Mechanisms of endocrine resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

ERGDB: Estrogen Responsive Genes Database

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Biological determinants of endocrine resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Biological mechanisms and clinical implications of endocrine resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Structure and regulation of Src family kinases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Fyn: a novel molecular target in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.138

31 March 2020

Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The absence of myristic acid decreases membrane binding of p60src but does not affect tyrosine protein kinase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

REporting recommendations for tumor MARKer prognostic studies (REMARK).

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24882577

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/ONC.2014.138

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882577%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38989597&oldid=1962118733"